{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:27Z","timestamp":1781179107376,"version":"3.54.1"},"reference-count":23,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chemoradiation with capecitabine radiotherapy (Cape\u2013RT) has been the standard of care as neoadjuvant treatment in locally advanced rectal cancer (LARC) for more than a decade. However, total neoadjuvant therapy has recently emerged as an alternative with the potential to impact survival outcomes; baseline outcomes with Cape\u2013RT in real-world practice in the Indian context are not well known.<\/jats:p>\n                  <jats:p>Treatment-naive patients with adenocarcinoma on histology and clinical-radiologically diagnosed LARC who received Cape\u2013RT from June 2014 to December 2021 after multidisciplinary discussion were included. Patients received a long course of conventionally fractionated external beam RT (45\u201350 Gy in 25#) with concurrent oral capecitabine at a dose of 1650\u2009mg\/m2\/day. Post approximately 6 to 8 weeks of completion of Cape\u2013RT, patients were evaluated clinically and by magnetic resonance imaging pelvis for total mesorectal excision (TME) in the multidisciplinary team meetings. The primary endpoint of the study was event-free survival (EFS), and the secondary endpoint was overall survival (OS) and pathological complete response (PCR) rates. EFS and OS were calculated using the Kaplan\u2013Meier method.<\/jats:p>\n                  <jats:p>A total of 1,189 patients with a median age of 49 years (range: 15\u201395) were identified and included. A significant proportion of patients had high-risk characteristics, such as T3\/T4 disease (94%) and node positivity (90%), and they involved circumferential resection margin (CRM) (51%) at baseline. Signet ring and mucinous histology were seen in 13 and 11% of patients. Two hundred and seventy-six patients (23%) required further consolidation chemotherapy (commonly CAPOX [capecitabine-oxaliplatin] or modified FOLFIRINOX [5-fluorouracil-leucovorin-irinotecan-oxaliplatin]) post-Cape\u2013RT prior to attempting surgery due to either persistent CRM positivity, clinical T4 disease, prostate abutment, sphincter involvement (248 patients, 21%), or extensive bulky disease with poor response (12 patients, 1%). Overall, 14 patients (6%) had an interruption in RT and 22 (8%) in chemotherapy. Post-Cape\u2013RT, with or without chemotherapy, 945 patients (79%) underwent TME. Chemotherapy post-TME was administered in 808 patients (78%). With a median follow-up of 54 months (range: 51.2\u201357.2), the 3- and 5-year EFS for the entire cohort was 73.2% (95% confidence interval [CI]: 70.6\u201375.8) and 64.3% (95% CI: 61.1\u201367.5), respectively, while the estimated 3- and 5-year OS was 81.3% (95% CI: 78.9\u201383.7) and 73% (95% CI: 70\u201376), respectively. On multivariate analysis, the presence of higher T stage (p\u2009&lt;\u20090.001) and signet ring histology (p\u2009=\u20090.004) predicted inferior OS.<\/jats:p>\n                  <jats:p>Real-world data in a less-resourced setting concurs with published prospective and Western real-world data. This provides confidence in implementing consolidation chemotherapy in total neoadjuvant settings in countries with fewer resources.<\/jats:p>","DOI":"10.1055\/s-0045-1806957","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T19:36:24Z","timestamp":1743708984000},"page":"257-264","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Data on the Practice of Chemoradiation with Select Cohort Consolidation Chemotherapy in High-Risk Locally Advanced Rectal Cancers (SOLAR study)"],"prefix":"10.25259","volume":"14","author":[{"given":"Mounika","family":"Yallala","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-7782","authenticated-orcid":false,"given":"Rahul","family":"Krishnatry","sequence":"additional","affiliation":[{"name":"Department of Radiational Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6440-2186","authenticated-orcid":false,"given":"Prabhat Ghanshyam","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Baheti","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanish","family":"Saklani","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3893-1287","authenticated-orcid":false,"given":"Reena","family":"Engineer","sequence":"additional","affiliation":[{"name":"Department of Radiational Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman K.","family":"Ankathi","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Kazi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Desouza","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0067-4748","authenticated-orcid":false,"given":"Vikas","family":"Ostwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"03","key":"ref1","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"R L Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"ref3","first-page":"CD008368","article-title":"Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer","volume":"12","author":"K McCarthy","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref4","first-page":"CD004078","article-title":"Postoperative adjuvant chemotherapy in rectal cancer operated for cure","volume":"2012","author":"S H Petersen","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1007\/s00268-019-05060-5","article-title":"Compliance to adjuvant chemotherapy of patients who underwent surgery for rectal cancer: report from a multi-institutional research network","volume":"43","author":"G M Mari","year":"2019","journal-title":"World J Surg"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"T Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.radonc.2020.03.011","article-title":"Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial","volume":"147","author":"M JM van der Valk","year":"2020","journal-title":"Radiother Oncol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/jgo.2018.10.01","article-title":"Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes","volume":"10","author":"V Ostwal","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"02","key":"ref9","first-page":"291","article-title":"Prognostic factors affecting recurrence and survival in patients with locally advanced rectal cancer","volume":"17","author":"D Koca","year":"2012","journal-title":"J Balkan Union Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"L H Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/jcrt.jcrt_225_22","article-title":"Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and \u2018salvage\u2019 in patients with high risk locally advanced rectal cancers - tolerance and early outcomes","volume":"20","author":"R Prajapati","year":"2024","journal-title":"J Cancer Res Ther"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00423-021-02143-7","article-title":"Outcomes of exenteration in cT4 and fixed cT3 stage primary rectal adenocarcinoma: a subgroup analysis of consolidation chemotherapy following neoadjuvant concurrent chemoradiotherapy","volume":"406","author":"N A Kumar","year":"2021","journal-title":"Langenbecks Arch Surg"},{"issue":"23","key":"ref13","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJM198506063122301","article-title":"Prolongation of the disease-free interval in surgically treated rectal carcinoma","volume":"312","author":"Gastrointestinal Tumor Study Group","year":"1985","journal-title":"N Engl J Med"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199103143241101","article-title":"Effective surgical adjuvant therapy for high-risk rectal carcinoma","volume":"324","author":"J E Krook","year":"1991","journal-title":"N Engl J Med"},{"issue":"16","key":"ref15","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"R Sauer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"31","key":"ref16","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1200\/JCO.2009.22.0467","article-title":"Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03","volume":"27","author":"M S Roh","year":"2009","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2003.12.006","article-title":"Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy","volume":"72","author":"K Bujko","year":"2004","journal-title":"Radiother Oncol"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","article-title":"Long-course preoperative chemoradiation versus 5 \u00d7 5\u2009Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study","volume":"30","author":"B Cise\u0142","year":"2019","journal-title":"Ann Oncol"},{"issue":"31","key":"ref19","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"S Y Ngan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3346\/jkms.2006.21.1.52","article-title":"Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer","volume":"21","author":"J S Kim","year":"2006","journal-title":"J Korean Med Sci"},{"issue":"17","key":"ref21","doi-asserted-by":"crossref","first-page":"e15241","DOI":"10.1097\/MD.0000000000015241","article-title":"Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: a meta-analysis","volume":"98","author":"J Zhu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial","volume":"13","author":"R D Hofheinz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"R R Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2024.42.3_suppl.40","article-title":"International real-world study of total neoadjuvant therapy (TNT) for locally advanced rectal cancer (Larc)","volume":"42","author":"A Audisio","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1806957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:09Z","timestamp":1781176389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/real-world-data-on-the-practice-of-chemoradiation-with-select-cohort-consolidation-chemotherapy-in-high-risk-locally-advanced-rectal-cancers-solar-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1806957","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}